NateraNTRA

NASDAQ · USA · Segment 6 of 8 in the Medicine, pharma & life science value chain: Diagnostics

Genetic testing put to three uses: Panorama screens pregnancies, Signatera works in oncology, and a third line covers transplant medicine.

Diagnostics: Tests, imaging and assays that support clinical decision-making.

Key metrics

Market cap

$44.6B

Price

$327.72

Today

−1.3%

Return YTD

+44.9%

Return 1Y

+105.0%

P/E

—

P/S

16.5

P/B

24.5

Data as of 2026-08-25 · updates daily after U.S. close

Theme exposure

Genetic diagnosticsOncology testingPrenatal screening

In the value chain

Products & services

Prenatal screening (Panorama)
Oncology testing (Signatera)
Transplant diagnostics

Competitors

Guardant Health
Exact Sciences
Myriad Genetics

Risks

Reimbursement & coverage
Patent disputes

Supply chain

Supplies →

UnitedHealthUNH

← Suppliers

IlluminaILMN

Full supply chain for NTRA →

Same segment: Diagnostics

Abbott LaboratoriesABT IDEXX LaboratoriesIDXX LabcorpLH Quest DiagnosticsDGX HologicHOLX Bio-Rad LaboratoriesBIO

Compare NTRA

NTRA vs ABT NTRA vs IDXX NTRA vs LH NTRA vs DGX NTRA vs HOLX NTRA vs BIO

See where Natera sits in the full Medicine, pharma & life science map: every segment from upstream suppliers to end markets, with daily metrics.Open the Life science value chain →